News
Press Release
September 12, 2023

Apmonia Therapeutics announces a new licensing agreement with SATT Nord to strengthen its portfolio of innovative peptides for oncology

Apmonia Therapeutics announces a new licensing agreement with SATT Nord to strengthen its portfolio of innovative peptides for oncology. The full press release is shown above.

Latest news

News
Cover of the Apmonia Therapeutics press release of 12 November 2026
Press Release
November 12, 2026

Apmonia Therapeutics announces first patient treated in Phase 1/2a study of TAX2, a new approach to cancer immunotherapy

Read more
Cover of the Apmonia Therapeutics press release of February 3, 2026
Press Release
February 3, 2026

Apmonia Therapeutics secures €10 million to advance first-in-human development of first-in-class cancer therapy TAX2

Read more
Illustration of computational modeling of a protein interaction
Press Release
December 16, 2024

Apmonia Therapeutics strengthens its drug discovery capabilities and extends its collaboration with the Max Mousseron Institute of Biomolecules (IBMM)

Read more
Press Release
July 16, 2024

Apmonia Therapeutics to receive €2.5m grant and €7m equity investment from the European Innovation Council (EIC) as a laureate of the EIC Accelerator program

Read more